Formulations of valproate alter valproate metabolism: A single oral dose kinetic study

Therapeutic Drug Monitoring

Volumn 31, Issue 5, 2009, Pages 592-596

  Nagai, Goyo ^a   Ono, Shingo ^b   Yasui Furukori, Norio ^c   Nakamura, Akifumi ^a   Mihara, Kazuo ^a   Kondo, Tsuyoshi ^a  

^a UNIVERSITY OF THE RYUKYUS   (Japan)

^b TOKYO MEDICAL UNIVERSITY   (Japan)

^c HIROSAKI UNIVERSITY   (Japan)

Author keywords

4 en; Formulation; Metabolism; Pharmacokinetics; Valproate

Indexed keywords

DRUG METABOLITE; VALPROIC ACID;

ADULT; AREA UNDER THE CURVE; ARTICLE; BLOOD SAMPLING; CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; DRUG BLOOD LEVEL; DRUG DOSAGE FORM COMPARISON; DRUG FORMULATION; DRUG METABOLISM; DRUG OXIDATION; FATTY ACID OXIDATION; HUMAN; HUMAN EXPERIMENT; MALE; MAXIMUM PLASMA CONCENTRATION; MICROSOME; NORMAL HUMAN; PLASMA CONCENTRATION-TIME CURVE; PRIORITY JOURNAL; SINGLE DRUG DOSE; SLOW RELEASE FORMULATION; TIME TO MAXIMUM PLASMA CONCENTRATION;

ADMINISTRATION, ORAL; ADULT; CHEMISTRY, PHARMACEUTICAL; FATTY ACIDS, MONOUNSATURATED; GAS CHROMATOGRAPHY-MASS SPECTROMETRY; HUMANS; KINETICS; MALE; MICROSOMES; OXIDATION-REDUCTION; STRUCTURE-ACTIVITY RELATIONSHIP; VALPROIC ACID;

EID: 70349653062     PISSN: 01634356     EISSN: 15363694     Source Type: Journal    
DOI: 10.1097/FTD.0b013e3181b777f9     Document Type: Article

References (24)

1. Zimmerman HJ, Ishak KG. Valproate-induced hepatic injury: analyses of 23 fatal cases. Hepatology. 1982;2:591-597.
2. Kesterson JW, Granneman GR, Machinist JM. The hepatotoxicity of valproic acid and its metabolites in rats. I. Toxicologic, biochemical and histopathologic studies. Hepatology. 1984;4:1143-1152.
3. Dreifuss FE, Santilli N, Langer DH, et al. Valproic acid hepatic fatalities: a retrospective review. Neurology. 1987;37:379-385.
4. Robert E, Guibaud P. Maternal valproic acid and congenital neural tube defects. Lancet. 1982;2:937.
5. Jäger-Roman E, Deichl A, Jakob S, et al. Fetal growth, major malformations, and minor anomalies in infants born to women receiving valproic acid. J Pediatr. 1986;108:997-1004.
6. Kaneko S, Otani K, Fukushima Y, et al. Teratogenicity of antiepileptic drugs: analysis of possible risk factors. Epilepsia. 1988; 29:459-467.
7. Kingsley E, Tweedale R, Tolman KG. Hepatotoxicity of sodium valproate and other anticonvulsants in rat hepatocyte cultures. Epilepsia. 1980;21: 699-704. (Pubitemid 11092125)
8. Nau H, Zierer R, Spielmann H, et al. A new model for embryotoxicity testing: teratogenicity and pharmacokinetics of valproic acid following constant-rate administration in the mouse using human therapeutic drug and metabolite concentrations. Life Sci. 1981;29:2803-2814.
9. Kondo T, Kaneko S. Teratogenicity of valproate: pharmacokinetic aspects. Eur J Neurol. 1995;2(Suppl 4):41-45.
10. Vajda FJ, O'brien TJ, Hitchcock A, et al. Critical relationship between sodium valproate dose and human teratogenicity: results of the Australian register of anti-epileptic drugs in pregnancy. J Clin Neurosci. 2004;11: 854-858.
11. Meador KJ, Baker GA, Finnell RH, et al. In utero antiepileptic drug exposure: fetal death and malformations. Neurology. 2006;67:407-412.
12. Nau H, Löscher W. Valproic acid and metabolites: pharmacological and toxicological studies. Epilepsia. 1984;25(Suppl 1):S14-S22.
13. Rettenmeier AW, Gordon WP, Barnes H, et al. Studies on the metabolic fate of valproic acid in the rat using stable isotope techniques. Xenobiotica. 1987;17:1147-1157.
14. Rettie AE, Rettenmeier AW, Howald WN, et al. Cytochrome P-450- catalyzed formation of delta 4-VPA, a toxic metabolite of valproic acid. Science. 1987;235:890-893.
15. Sadeque AJ, Fisher MB, Korzekwa KR, et al. Human CYP2C9 and CYP2A6 mediate formation of the hepatotoxin 4-ene-valproic acid. J Pharmacol Exp Ther. 1997;283:698-703.
16. Ho PC, Abbott FS, Zanger UM, et al. Influence of CYP2C9 genotypes on the formation of a hepatotoxic metabolite of valproic acid in human liver microsomes. Pharmacogenomics J. 2003;3:335-342.
17. KochenW, Schneider A, Ritz A. Abnormal metabolism of valproic acid in fatal hepatic failure. Eur J Pediatr. 1983;141:30-35.
18. Kuhara T, Inoue Y,Matsumoto M, et al. Altered metabolic profiles of valproic acid in a patient with Reye's syndrome. Clin Chim Acta. 1985;145:135-142.
19. Kondo T, Kaneko S, Otani K, et al. Associations between risk factors for valproate hepatotoxicity and altered valproate metabolism. Epilepsia. 1992;33:172-177.
20. Tatsuhara T, Muro H, Matsuda Y, et al. Pharmacokinetics of valproic acid and its metabolites after a single oral administration of a sustained-release preparation of sodium valproate (KW-6066N) [in Japanese, abstract in English]. Jpn J Clin Pharmacol Ther. 1988;19:749-757.
21. Kondo T, Tokinaga N, Suzuki A, et al. Altered pharmacokinetics and metabolism of valproate after replacement of conventional valproate with the slow-release formulation in epileptic patients. Pharmacol Toxicol. 2002;90:135-138.
22. Nau H,WittfohtW, Schafer H, et al. Valproic acid and several metabolites: quantitative determination in serum, urine, breast milk and tissues by gas chromatography-mass spectrometry using selected ion monitoring. J Chromatogr. 1981;226:69-78.
23. Kondo T, Otani K, Hirano T, et al. The effects of phenytoin and carbamazepine on serum concentrations of mono-unsaturated metabolites of valproic acid. Br J Clin Pharmacol. 1990;29:116-119.
24. Nau H. Teratogenic valproic acid concentrations: infusion by implanted minipumps vs conventional injection regimen in the mouse. Toxicol Appl Pharmacol. 1985;80:243-250.